Resveratrol ameliorates maternal and post-weaning high-fat diet-induced nonalcoholic fatty liver disease via renin-angiotensin system

Actein ameliorates hepatic steatosis and fibrosis in high fat diet-induced NAFLD by regulation of insulin and leptin resistant

(2018) Hong-Jun Chen et al.   BIOMEDICINE & PHARMACOTHERAPY

Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis

(2018) Alessandro Mantovani et al.   DIABETES CARE

Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?

(2018) Amedeo Lonardo et al.   JOURNAL OF HEPATOLOGY

Emerging roles of SIRT1 in fatty liver diseases

(2017) Ren-Bo Ding et al.   International Journal of Biological Sciences

Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis

(2016) Stefano Ballestri et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Lipid disorder and intrahepatic renin-angiotensin system activation synergistically contribute to non-alcoholic fatty liver disease

(2016) Yu Wu et al.   LIVER INTERNATIONAL

The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)

(2016) Elena Buzzetti et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Sirtuins and nonalcoholic fatty liver disease

(2016) Fatiha Nassir et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Hepatic Macrosteatosis Is Partially Converted to Microsteatosis by Melatonin Supplementation in ob/ob Mice Non-Alcoholic Fatty Liver Disease

(2016) Alessandra Stacchiotti et al.   PLoS One

Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis

(2016) Takaomi Kessoku et al.   Scientific Reports

The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study

(2015) Forouzan Faghihzadeh et al.   BRITISH JOURNAL OF NUTRITION

Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial

(2015) Shihui Chen et al.   DIGESTIVE AND LIVER DISEASE

Fucoidan ameliorates steatohepatitis and insulin resistance by suppressing oxidative stress and inflammatory cytokines in experimental non-alcoholic fatty liver disease

(2015) Gehan H. Heeba et al.   ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY

Diverse Roles of SIRT1 in Cancer Biology and Lipid Metabolism

(2015) Glenn Simmons et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Jinlida reduces insulin resistance and ameliorates liver oxidative stress in high-fat fed rats

(2015) Yixuan Liu et al.   JOURNAL OF ETHNOPHARMACOLOGY

Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease

(2014) Veronique S. Chachay et al.   Clinical Gastroenterology and Hepatology

Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease

(2014) Forouzan Faghihzadeh et al.   NUTRITION RESEARCH

Angiotensin 1–7: A peptide for preventing and treating metabolic syndrome

(2014) Sérgio Henrique Sousa Santos et al.   PEPTIDES

The role of renin-angiotensin system modulation on treatment and prevention of liver diseases

(2014) Simone Moreira de Macêdo et al.   PEPTIDES

SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease

(2013) Yasar Colak et al.   MEDICAL SCIENCE MONITOR

High Fat Diet Induces Liver Steatosis and Early Dysregulation of Iron Metabolism in Rats

(2013) Rosaria Meli et al.   PLoS One

Adipokines Mediate Inflammation and Insulin Resistance

(2013) Hyokjoon Kwon et al.   Frontiers in Endocrinology

SIRT1 and energy metabolism

(2012) X. Li   ACTA BIOCHIMICA ET BIOPHYSICA SINICA

Hepatic Steatosis Index and Lipid Accumulation Product as middle-term predictors of incident metabolic syndrome in a large population sample: data from the Brisighella Heart Study

(2012) Arrigo F. G. Cicero et al.   Internal and Emergency Medicine

Decreased hepatic gluconeogenesis in transgenic rats with increased circulating angiotensin-(1-7)

(2012) Victor Bilman et al.   PEPTIDES

Negative regulation of inflammation by SIRT1

(2012) Jun Xie et al.   PHARMACOLOGICAL RESEARCH

Is alanine aminotransferase level a surrogate biomarker of hepatic apoptosis in nonalcoholic fatty liver disease?

(2010) Billur Canbakan et al.   Biomarkers in Medicine

ACE2 and Diabetes: ACE of ACEs?

(2010) D. Batlle et al.   DIABETES

Hepatocyte-Specific Deletion of SIRT1 Alters Fatty Acid Metabolism and Results in Hepatic Steatosis and Inflammation

(2009) Aparna Purushotham et al.   Cell Metabolism

Upregulation of angiotensin-converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors

(2009) Mao-liang Huang et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Metabolic benefits from Sirt1 and Sirt1 activators

(2009) Nilika Chaudhary et al.   CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE

Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis

(2008) Robson A. S. Santos et al.   EXPERIMENTAL PHYSIOLOGY

Sirt1 protects against high-fat diet-induced metabolic damage

(2008) P. T. Pfluger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA